Share Name Share Symbol Market Type Share ISIN Share Description
Sareum Holdings LSE:SAR London Ordinary Share GB00B02RFS12 ORD 0.025P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.025p -2.33% 1.05p 1.00p 1.10p 1.075p 1.05p 1.075p 3,557,886 14:01:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -1.2 -0.0 - 27.77

Sareum Share Discussion Threads

Showing 27926 to 27949 of 27950 messages
Chat Pages: 1118  1117  1116  1115  1114  1113  1112  1111  1110  1109  1108  1107  Older
DateSubjectAuthorDiscuss
17/10/2017
01:06
For reference. Abiterone (the last compund icr outlicenced is 1bn a year sales. Every 1bn equates to roughly 1p a year royalties on our chk1 deal. Gemcitibane when under patent c 15 years ago was $2bn a year (i guess 4bn at current values). Keytruda expextex to be c $8bn. My own valuation assuming all stages passed is 4p milestones then 4p a year divis. But its my risk. Gla dyor etc
mrsapeslaptop
16/10/2017
23:48
Yes and no. Having listwned to the sierra webcasts there is some new stuff that the experts have referred to other chk1 data but not ours specifically. Notably lillys stalled compound. What was struking is that our combo approach is a first. We are not potentiating the effect of gemcitibane. Rather we are microdosing gem at low levels that dont cause side effects to potentiate chk1. 23 times combo potentiation in pancreatic preclinical reported " will replace chemo as the frontline standatd of care" was a quote. Worth a listen on the sierra website. I suspect the poster is specific to our compound supporting the principles alluded to in the webcasts.
mrsapeslaptop
16/10/2017
23:31
Sierra has just made the following announcement; I am assuming that the preclinical data that they will report is work done before Sierra took over and pretty much in the public domain , and that there will be no information on the results of ork done since Sierra took over. Is that how you all read this? quote Sierra Oncology to Report Chk1 Inhibitor SRA737 Preclinical Data at AACR-NCI-EORTC 2017 - Chk1 inhibitor SRA737 demonstrates chemical synthetic lethality with replication stress-inducing agents, including potentiation by novel low-dose gemcitabine combination, in preclinical models of cancer - VANCOUVER, Oct. 16, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced that it will report preclinical data supporting the clinical development strategy for its Chk1 inhibitor, SRA737, in a poster to be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held from October 26 - 30, 2017 in Philadelphia, Pennsylvania. SRA737 is currently being investigated in two Phase 1 clinical trials in patients with advanced cancers; as a monotherapy, and in combination with low-dose gemcitabine. Title: The Chk1 inhibitor, SRA737, demonstrates chemical synthetic lethality with replication stress-inducing agents, including novel low-dose gemcitabine, in preclinical models of cancer. Poster #181; Abstract #B181: Session: Poster Session B; Therapeutic Agents: Small-Molecule Kinase Inhibitors Date and Time: Sunday, October 29, 2017, 12:30 PM – 4:00 PM Location: Hall E, Pennsylvania Convention Center The Poster will be available October 29, 2017 on the company's website at www.sierraoncology.com. unquote
cerrito
16/10/2017
21:07
our chk1 the combination of SRA737 and gemcitabine induces γ-H2A.X and p-RPA 3- to 5-fold over gemcitabine alone in tumor xenografts. Moreover, the combination inhibits tumor growth by 64% following administration of both agents at 100 mg/kg in a gemcitabine-insensitive patient-derived xenograft (PDX) model of bladder cancer. Importantly, SRA737 also synergizes with subtherapeutic doses of gemcitabine (40 mg/kg) in xenograft models of colorectal adenocarcinoma and osteosarcoma, indications where gemcitabine is not standard of care.
skez13
16/10/2017
16:10
Hi cerrito. There are some other tyk2 but they all seem to be discontininued. Eg celzome. Only us unlicenced of live programs. Competition is bms. Pfizer and now celgenr.
mrsapeslaptop
16/10/2017
15:53
What's Happened to the graph?chart?
spacedust
16/10/2017
11:56
As someone who missed the Celgene/Nimbus announcement, thanks Mrs A Are you saying the two projects that SAR have in TYK2 are the only unlicensed ones in the world? I am mystified that I cannot find any news on SAR’s progress in this since the February interims and this will be along with Aurora the two areas of focus when we get the prelims in the next fortnight. SAR do not need the money per se to progress TYK2 but as they say a very good discipline for them to be associated with people like SRI.
cerrito
13/10/2017
12:00
for those that missed it. Celgene took an option on the Nimbus Tyk2 program last week. that leaves only SAR with a tyk2 compound available to licence. tick tock. interest is there. we are the only game in town now....
mrsapeslaptop
12/10/2017
13:04
Walter: Liking ARS more and more each day :D)
waleoilbeefhooked
12/10/2017
08:51
o/t WOBH: ARS looking a bit tasty ! :-)
walter walcarpets
11/10/2017
12:59
I see that Sierra making another presentation and have been rewarded with their share price at a one year high. I am assuming that the recent increase in SAR’s price and trading volumes have been as a result of SRA’s increased profile. We will have the prelims in 2/3 weeks time-I need to say I would be pleasantly surprised if there has been a meaningful advance on Aurora and do not know what to expect on the two TYK programmes Sierra Oncology to Present at the 2017 BIO Investor Forum - "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 11:00 am PT on October 17, 2017 - VANCOUVER, Oct 11, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company entitled "Beyond PARP – Next Generation DDR Therapeutics" at the 2017 BIO Investor Forum in San Francisco. The presentation is scheduled for 11:00 am PT on Tuesday, October 17th. A live audio webcast and archive of the presentation will be accessible through www.sierraoncology.com
cerrito
11/10/2017
08:22
Goosey shorting? :D)
waleoilbeefhooked
10/10/2017
23:59
do not fret .....wolfie is still around if hissy fevvers pops its long neck up again
wolf4
10/10/2017
21:19
I like sar
spacedust
10/10/2017
15:46
We need somebody big to say they like us then it's all bets off!.
bryet
10/10/2017
15:36
Oh norma don't waken him up from his drunken stupor ....... it's been really nice here just recently. WOBH
waleoilbeefhooked
10/10/2017
15:33
Goosey is very quiet. Can't think why?
norma_stitts
10/10/2017
12:43
maybe we are reading his posts wrong? and should read it from the end?
skez13
10/10/2017
12:04
You messed up there livup....you should have had capitals at the start of your post.
molatovkid
10/10/2017
10:48
is this something NEW THE POWER THAT BE IS RUNNING??? DON'T PUT THE REGULAR RNS FROM YESTERDAY UP SO NO ONE SEE IT WHY ARE THEY HIDING THIS LITTLE GEM AND KEEPING share price DOWN REGARDS
livup967
10/10/2017
08:44
Cerrito - yes, there are some slow people around....they will soon catch on.
barkboo
09/10/2017
22:29
We have had quite busy trading over the last three days by SAR standards 12m,13m and 21m shares
cerrito
09/10/2017
21:47
Single or double tick up is fine by me every other day. It can carry on like this for the rest of the year
spacedust
09/10/2017
15:32
wait for the real news ...
skez13
Chat Pages: 1118  1117  1116  1115  1114  1113  1112  1111  1110  1109  1108  1107  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20171017 13:26:38